Neuroprotective effects of glycine for therapy of acute ischaemic stroke - PubMed (original) (raw)
Clinical Trial
. 2000 Jan-Feb;10(1):49-60.
doi: 10.1159/000016025.
Affiliations
- PMID: 10629347
- DOI: 10.1159/000016025
Clinical Trial
Neuroprotective effects of glycine for therapy of acute ischaemic stroke
E I Gusev et al. Cerebrovasc Dis. 2000 Jan-Feb.
Abstract
The aim of this randomized, double-blind, placebo-controlled trial was to assess the safety and the efficacy of the pharmaceutic drug glycine in 200 patients with acute (<6 h) ischaemic stroke in the carotid artery territory. Fifty patients received placebo, 49 glycine 0.5 g/day, 51 glycine 1.0 g/day and 50 glycine 2.0 g/day for 5 days in each group. The efficacy of glycine was assessed by clinical analysis, by an enzyme-linked immunosorbent assay of levels of blood serum autoantibodies to NMDA-binding proteines, by detection of excitatory (glutamate, aspartate) and inhibitory (glycine, GABA) amino acid concentrations and lipid peroxidation products (TBARS) in CSF. The trial confirmed the safety profile of the glycine treatment. Slight sedation was observed in 9 patients (4. 5%) as a side-effect. Other marked side-effects or adverse events were absent. The glycine treatment at the dose of 1.0-2.0 g/day was accompanied by a tendency to a decreased 30-day mortality (5.9% in 1. 0 g/day glycine and 10% in 2.0 g/day glycine groups vs. 14% in the placebo and 14.3% in 0.5 g/day glycine groups), to an improved clinical outcome on the Orgogozo Stroke Scale (p < 0.01) and the Scandinavian Stroke Scale (p < 0.01) and to a favourable functional outcome on the Barthel index (p < 0.01 in 1.0 g/day glycine vs. placebo group in patients with no or mild disability). An early normalization of autoantibody titres to NMDA-binding proteins in serum was found (p < 0.01 vs. placebo), a reduction of glutamate and aspartate levels (p < 0.05 vs. placebo), an increase in GABA concentrations (p < 0.01 vs. placebo in severe stroke patients) and also a reduction of TBARS levels (p < 0.05 vs. placebo) in CSF by day 3. Thus, the trial suggests that sublingual application of 1.0-2. 0 g/day glycine started within 6 h after the onset of acute ischaemic stroke in the carotid artery territory is safe and can exert favourable clinical effects. These results will be verified in further trials with a larger number of patients.
Copyright 2000 S. Karger AG, Basel
Similar articles
- [Neuroprotective effects of glycine in the acute period of ischemic stroke].
Gusev EI, Skvortsova VI, Komissarova IA, Dambinova SA, Raevskiĭ KS, Alekseev AA, Bashkatova VG, Kovalenko AV, Kudrin VS, Iakovleva EV. Gusev EI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(2):12-20. Zh Nevrol Psikhiatr Im S S Korsakova. 1999. PMID: 10081129 Clinical Trial. Russian. - Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
Diener HC, AlKhedr A, Busse O, Hacke W, Zingmark PH, Jonsson N, Basun H; Study group. Diener HC, et al. J Neurol. 2002 May;249(5):561-8. doi: 10.1007/s004150200065. J Neurol. 2002. PMID: 12021946 Clinical Trial. - Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial.
Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P; GAIN Phase II European Study Group. Lees KR, et al. Cerebrovasc Dis. 2001;11(1):20-9. doi: 10.1159/000047607. Cerebrovasc Dis. 2001. PMID: 11173790 Clinical Trial. - Granulocyte-Colony Stimulating Factor (G-CSF) for stroke: an individual patient data meta-analysis.
England TJ, Sprigg N, Alasheev AM, Belkin AA, Kumar A, Prasad K, Bath PM. England TJ, et al. Sci Rep. 2016 Nov 15;6:36567. doi: 10.1038/srep36567. Sci Rep. 2016. PMID: 27845349 Free PMC article. Review. - Glycine--an inert amino acid comes alive.
Roth E, Zellner M, Wessner B, Strasser E, Manhart N, Oehler R, Spittler A. Roth E, et al. Nutrition. 2003 Sep;19(9):817-8. doi: 10.1016/s0899-9007(03)00100-x. Nutrition. 2003. PMID: 12921899 Review. No abstract available.
Cited by
- Pinocembrin attenuates hemorrhagic transformation after delayed t-PA treatment in thromboembolic stroke rats by regulating endogenous metabolites.
Kong LL, Gao L, Wang KX, Liu NN, Liu CD, Ma GD, Yang HG, Qin XM, Du GH. Kong LL, et al. Acta Pharmacol Sin. 2021 Aug;42(8):1223-1234. doi: 10.1038/s41401-021-00664-x. Epub 2021 Apr 15. Acta Pharmacol Sin. 2021. PMID: 33859344 Free PMC article. - Metabolomic Profile of Posner-Schlossman Syndrome: A Gas Chromatography Time-of-Flight Mass Spectrometry-Based Approach Using Aqueous Humor.
Wang H, Zhai R, Sun Q, Wu Y, Wang Z, Fang J, Kong X. Wang H, et al. Front Pharmacol. 2019 Nov 7;10:1322. doi: 10.3389/fphar.2019.01322. eCollection 2019. Front Pharmacol. 2019. PMID: 31780941 Free PMC article. - Glycine confers neuroprotection through microRNA-301a/PTEN signaling.
Chen J, Zhuang Y, Zhang ZF, Wang S, Jin P, He C, Hu PC, Wang ZF, Li ZQ, Xia GM, Li G, Wang Y, Wan Q. Chen J, et al. Mol Brain. 2016 May 26;9(1):59. doi: 10.1186/s13041-016-0241-3. Mol Brain. 2016. PMID: 27230112 Free PMC article. - Dynamic metabolites profile of cerebral ischemia/reperfusion revealed by (1)H NMR-based metabolomics contributes to potential biomarkers.
Wang Y, Wang YG, Ma TF, Li M, Gu SL. Wang Y, et al. Int J Clin Exp Pathol. 2014 Jun 15;7(7):4067-75. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120785 Free PMC article. - Glycine: The Smallest Anti-Inflammatory Micronutrient.
Aguayo-Cerón KA, Sánchez-Muñoz F, Gutierrez-Rojas RA, Acevedo-Villavicencio LN, Flores-Zarate AV, Huang F, Giacoman-Martinez A, Villafaña S, Romero-Nava R. Aguayo-Cerón KA, et al. Int J Mol Sci. 2023 Jul 8;24(14):11236. doi: 10.3390/ijms241411236. Int J Mol Sci. 2023. PMID: 37510995 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical